Orizal (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil and amlodipine, the active ingredient in Orizal, is an Angiotensin II receptor blocker (ARB) and calcium channel blocker presented as a oral tablet for hypertension management in adults. It lowers blood pressure by targeting two complementary pathways involved in vascular tone.

GNH USA supplies Orizal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orizal is an antihypertensive medication that acts on the renin‑angiotensin system and vascular smooth‑muscle calcium channels to control high blood pressure. - Hypertension: helps achieve target blood pressure and reduces cardiovascular risk. - Chronic kidney disease with hypertension: assists in slowing progression by controlling systemic pressure. - Heart failure with reduced ejection fraction: used as part of combination therapy to improve outcomes.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headed dizziness. - Headache. - Peripheral edema. - Flushing. - Fatigue. - Nasal congestion.

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue. - Severe hypotension. - Acute kidney injury. - Hepatic dysfunction. - Significant electrolyte disturbances. - Myocardial infarction related to abrupt blood pressure changes.

Before initiating therapy, consider the following precautions: - Pregnancy: contraindicated in pregnancy due to fetal risk. - Renal impairment: monitor kidney function and adjust if necessary. - Hepatic impairment: use with caution and observe liver enzymes. - Electrolyte balance: check potassium and sodium levels regularly. - Concomitant antihypertensives: avoid excessive blood pressure lowering. - Store at below 25°C: keep in the original packaging .

Orizal may interact with several medicines that affect blood pressure or renal function.

Major Interactions (​ ​ )​: - Potassium‑rich ​  ​  or  ​  ​  ​  ​   ​  ​  ​   ​  ​   ​  ​  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​-  ​  ​  ​  ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - ACE‑inhibitors/ARBs combined with aliskiren: ​ ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ - NSAIDs: ​ ​​ ​ ​ ​ ​ ​ ​ ​​ - Lithium  ​  ​   -    ​  ​  

bsp     -        -        -  \\\\\\\\\\